Evoke Pharma
EVOK
EVOK was delisted on the 16th of December, 2025.
23 hedge funds and large institutions have $5.58M invested in Evoke Pharma in 2017 Q1 according to their latest regulatory filings, with 13 funds opening new positions, 6 increasing their positions, 2 reducing their positions, and 2 closing their positions.
550% more first-time investments, than exits
New positions opened: 13 | Existing positions closed: 2
371% more capital invested
Capital invested by funds: $1.19M → $5.58M (+$4.4M)
200% more repeat investments, than reductions
Existing positions increased: 6 | Existing positions reduced: 2
64% more funds holding
Funds holding: 14 → 23 (+9)
6.96% more ownership
Funds ownership: 4.75% → 11.7% (+7%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
SFM
Sphera Funds Management
Tel Aviv,
Israel
|
+$1.42M |
| 2 |
Vanguard Group
Malvern,
Pennsylvania
|
+$666K |
| 3 |
KCM
Knoll Capital Management
Miami,
Florida
|
+$498K |
| 4 |
SOMRS
State of Michigan Retirement System
Lansing,
Michigan
|
+$319K |
| 5 |
PM
Precept Management
Dallas,
Texas
|
+$270K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Citadel Advisors
Miami,
Florida
|
-$34K |
| 2 |
AIM
Acrospire Investment Management
Chicago,
Illinois
|
-$20.1K |
| 3 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
-$20K |
| 4 |
VKH
Virtu KCG Holdings
New York
|
-$4.92K |
EVOK Hedge Fund Activity: Q1 2017 in Review
23 of the 4,034 institutional investors tracked by Wall St. Rank reported a position in Evoke Pharma (EVOK) for Q1 2017, worth a combined $5.58M — up 371% from $1.19M a quarter earlier.
Buyers outnumbered sellers: 13 funds opened new EVOK positions and 2 closed out — a net gain of 11 holders — while 6 added to existing stakes and 2 trimmed.
The largest buyer was Sphera Funds Management, opening a new position worth an estimated $1.42M. The largest seller was Citadel Advisors, exiting entirely with an estimated $34K sold.
- 23 institutional investors held Evoke Pharma (EVOK) as of Q1 2017, up from 14 in Q4 2016.
- Funds reported $5.58M of Evoke Pharma stock for Q1 2017, up 371% quarter-over-quarter.
- 13 funds opened new Evoke Pharma positions in Q1 2017 and 2 closed out, a net change of +11 holders.
- The largest Evoke Pharma buyer in Q1 2017 was Sphera Funds Management, an estimated $1.42M added.
- The largest Evoke Pharma seller in Q1 2017 was Citadel Advisors, an estimated $34K sold.
Based on aggregated 13F filings for Q1 2017.